Acelyrin and Akero, pioneers in immunological and metabolic therapies
Founded in 2020 by Shao-Lee Lin, Acelyrin has quickly established itself as a leader in the field of immunological treatments. The company focuses its efforts on developing next-generation drugs for chronic inflammatory diseases, such as psoriatic arthritis and atopic dermatitis. Their innovative approach is based on a deep understanding of immune mechanisms, offering more targeted and better-tolerated therapies.
Akero Therapeutics, for its part, focuses on metabolic diseases, including non-alcoholic steatohepatitis (NASH), a liver disease with often serious consequences. By exploiting promising molecules, Akero is developing treatments capable of reducing inflammation and improving liver function, offering new perspectives for patients.
VectorY Therapeutics, the specialist in gene therapy for rare diseases
Based in the Netherlands, VectorY Therapeutics is committed to an ambitious mission: using gene therapy to treat previously neglected rare diseases. Founded in 2020, the company leverages advanced viral vectors to deliver corrective genes directly to targeted cells. This approach promises long-lasting, even curative, treatments for complex neurological and neuromuscular pathologies.
Under the leadership of Sander van Deventer, a recognized expert in the field of biotechnology, VectorY Therapeutics has established itself as a major player, attracting significant investment and collaborating with leading research institutions.
Javara reinvents clinical trials
In the field of clinical trials, Javara is disrupting traditional practices by putting patients at the heart of the process. Founded in 2018 by Jennifer Byrne, this American company democratizes access to clinical trials by collaborating closely with hospitals, physicians, and local communities.
Javara's major innovations:
• Increased accessibility: By integrating trials directly into primary care, Javara facilitates patient participation and reduces logistical barriers.
• Technology and personalization: The company uses digital tools to track participants, ensure their comfort and optimize study results.
• Speed of integration: by modernizing processes, Javara accelerates the time it takes new treatments to market.
This innovative approach makes it possible to respond more effectively to patient needs while stimulating medical innovation, creating a virtuous circle between research and clinical care.
Solve Therapeutics, the Californian biotech company reinventing psychiatric treatments
Founded two years ago in California, Solve Therapeutics is already establishing itself as a rising star in biomedical research in North America. With $126 million in funding, the company is developing innovative treatments for major psychiatric conditions—such as Alzheimer's disease and autism spectrum disorders—that are still inaccessible to conventional therapies.
Led by a team of around twenty researchers, the company recently strengthened its expertise through the acquisition of Cereius, a pioneer in antibody-based therapies. Its multidisciplinary approach is based on a powerful scientific foundation and strategic partnerships with leading academic institutions.
Led by an experienced duo from the pharmaceutical industry, Solve Therapeutics embodies a new generation of biotech, combining scientific excellence, industrial ambition and long-term vision in the treatment of psychiatric illnesses.
These five companies are included in the Vintage FPCI Altaroc Odyssey .
.webp)
